Anti-Amyloid Alzheimer's Treatments, Explained

After decades of disappointment, the first treatments shown to slow the progression of Alzheimer's disease have arrived, and they have generated enormous hope and a good deal of confusion. The honest picture is that they represent a genuine scientific milestone and, at the same time, are far from the cure many people are longing for. Holding both truths is important for families weighing what they mean.

This is a companion piece for people trying to understand the new Alzheimer's treatments. It is not medical advice. It is an honest overview, and it is no substitute for the judgement of the specialists who would assess any individual.

What these treatments do

This new class of drugs, including the much-discussed lecanemab and donanemab, are antibody treatments given by infusion that target amyloid, a protein that builds up in the brains of people with Alzheimer's. By helping to clear amyloid, they have been shown in trials to modestly slow the decline of memory and thinking in early disease. This is the first time treatments have altered the course of the illness rather than only easing symptoms, which is why they matter scientifically. Our companion piece on living with Parkinson's describes another neurological condition where understanding treatment realistically matters.

The honest caveats

The crucial caveat is that the benefit, while real, is modest: these drugs slow decline somewhat, they do not stop or reverse the disease, and they do not restore lost memory. They also carry real risks, including a chance of brain swelling or small bleeds that must be monitored with scans, which is why careful specialist oversight is essential. They are given only in early Alzheimer's, require confirming that amyloid is present, and are not suitable for everyone. People weighing them have to balance a modest slowing of decline against burdens and risks, a genuinely personal decision.

Who they may help

These treatments are aimed at people in the early stages of Alzheimer's, and accessing them involves specialist assessment, tests to confirm the diagnosis and amyloid presence, and consideration of individual risk factors. Availability and approval differ by country and are evolving. People navigating memory concerns are helped by getting a proper assessment early, and our companion piece on how to be heard by your doctor may assist in seeking answers. Support and care remain central whatever treatment is or is not used, as our companion piece on stroke recovery reflects in a different context. None of this is a prescription for you; it is the ground families explore with specialists.

Hope, held realistically

What experts and families alike emphasise is that these drugs are a beginning, not an ending: proof that the disease can be influenced, and a foundation for better treatments to come, but not yet the breakthrough that changes everything. For some people they may be worth considering; for others the risks and modest benefit will not justify them. Honest expectations, here, are part of making a good decision.

If this is relevant to you, you can explore more in our Neurological Conditions collection.

This article is a companion, not medical advice. It reflects what people commonly describe; everyone is different. Decisions about Alzheimer's treatment require specialist assessment; for diagnosis and options, please speak with qualified clinicians.